Intervacc AB Logo

Intervacc AB

Develops recombinant protein vaccines and diagnostics for animal health, like Strangvac® for horses.

IVACC | ST

Overview

Corporate Details

ISIN(s):
SE0009607252 (+1 more)
LEI:
549300OICIVZBBZRNZ64
Country:
Sweden
Address:
Västertorpsvägen 135B, 129 44 Hägersten
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Intervacc AB is a biotechnology company that develops a new generation of vaccines for animal health. The company utilizes a modern technology platform based on recombinant protein fusions, stemming from research at the Karolinska Institutet and the Swedish University of Agricultural Sciences. Its lead product is Strangvac®, a vaccine against equine strangles. Through its subsidiary Nordvacc, Intervacc has an established sales organization with over 30 years of experience in the European animal health market. Another subsidiary, Mybac-Vettech, provides diagnostic laboratory services. The company's vaccines aim to strengthen animal health and wellbeing while contributing to the reduction of antibiotic use and combating antimicrobial resistance.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Intervacc AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Intervacc AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Intervacc AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-02-26 Lennart Johansson Other Other 813,474 691,452.90 SEK
2025-02-21 Lennart Johansson Other Other 324,156 275,532.60 SEK

Peer Companies

Company Country Ticker View
Global manufacturer of carbapenem antibiotic APIs for regulated markets.
South Korea 106190
HIKMA Pharmaceuticals PLC Logo
Develops & markets affordable generic & specialty medicines for markets in NA, MENA, & Europe.
United Kingdom HIK
HISAMITSU PHARMACEUTICAL CO.,INC. Logo
A global leader in transdermal drug delivery systems for OTC and prescription pain relief.
Japan 4530
HLB Genex, Inc. Logo
Develops custom enzymes & microbiome solutions for diagnostics, nutrition, and cosmetic markets.
South Korea 187420
HLB INC. Logo
A diversified group in pharma, shipbuilding, life sciences, and professional advisory services.
South Korea 028300
HLB Life Science CO.,LTD. Logo
Develops anti-cancer drugs and distributes IVD medical devices and lab supplies internationally.
South Korea 067630
HLB PANAGENE Co., LTD. Logo
A global leader in PNA technology for cancer diagnostics and precision medicine.
South Korea 046210
HLB Pep Co., Ltd. Logo
Develops and produces GMP peptides, APIs, and custom synthesis for the biopharma industry.
South Korea 196300
HLB PHARMACEUTICAL CO., LTD. Logo
Researches cancer drugs and offers pharmaceutical CMO and manufacturing services.
South Korea 047920
HLB SCIENCE Inc. Logo
Develops innovative therapeutics and diagnostics for infectious and neurodegenerative diseases.
South Korea 343090

Talk to a Data Expert

Have a question? We'll get back to you promptly.